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Despite the considerable research that has been devoted to 
 schizophrenia and depression over the last years, the understanding 
of the biological bases of these disabling disorders is still fragmen-
tary. Adoption-, twin- and family studies, provide clear evidence 
of strong genetic components to these mental disorders, although 
multiple loci are likely to be involved. The effect of pharmacologi-
cal intervention has hinted at speciﬁ  c neurotransmitter systems 
of etiological importance, but the lack of receptor speciﬁ  city of 
therapeutic drugs have thwarted any simple linkage of behavioural 
and molecular phenotypes. More recently brain imaging investiga-
tions, like PET and functional magnetic resonance imaging (fMRI), 
have identiﬁ  ed candidate structural and functional abnormalities, 
including work in identifying changes in networks of brain regions, 
but these ﬁ  ndings are still preliminary and need to be integrated 
with other accumulating knowledge.
Of particular interest in the last decade that is adding to the com-
plexity of the picture, is the realization that basic cognitive functions 
are seriously distorted, and that removal of core symptoms such 
as paranoia and hallucinations does not necessarily ameliorate the 
cognitive deﬁ  cits. It has also been shown that cognitive deﬁ  cits can 
occur before clinical symptoms in schizophrenia, in a prodromal 
phase of the disorder, pointing to a possible causal relationship 
between cognitive deﬁ  cits and outbreak of the disorder. Similarly, 
it has been reported that removing clinical symptoms in depression 
does not alleviate cognitive symptoms, like impaired concentration 
and focus of attention. However, it is still not possible to diagnose 
a patient from cognitive deﬁ  cits alone, or from a combination of 
clinical symptoms and cognitive deﬁ  cits, and structural and func-
tional neuroimaging data, although promising, have also not found 
the way to routine clinical practice.
The aim of the current special topic is to provide an update 
on research on cognitive and brain imaging research for the 
understanding of cognitive deﬁ  cits in these disorders, with a 
focus on recent developments in structural and functional neu-
roimaging, including recent advances in tracking of white matter 
ﬁ  bres, and electroencephalography (EEG) and novel computa-
tional measures.
Vince Calhoun et al. show how fMRI can be used not only to 
identifying regions where hemodynamic response amplitudes can 
differentiate between patient and control groups, but also how such 
amplitude based comparisons can estimate temporal correlations 
and compute maps of functional connectivity between regions. In 
their article, Calhoun et al. review work related to how these brain 
networks are pervasive also in a relaxed resting state, included the 
default mode network and how such analysis can provide novel 
approaches to yielding biomarkers for schizophrenia and other 
mental disorders, which can be described both in terms of disrupted 
local processing as well as altered global connectivity between large 
scale cortical networks. The paper also introduces new statisti-
cal approaches to functional connectivity, emphasizing the use of 
independent component analysis.
Bjørn Rishovd Rund reviews recent research and discusses 
whether schizophrenia is a neurodegenerative disorder, with progres-
sive neuronal degeneration as the illness progresses. Acknowledging 
that this issue has been discussed ever since the identiﬁ  cation of 
schizophrenia as a disorder of its own, Rund focuses on what can 
be learned from recent cognitive and brain imaging data. He takes 
the position that although there are reports of cognitive decline 
the longer the patient has been ill, and corresponding grey matter 
changes, there is no convincing evidence of a progressive neurode-
generative process after onset of illness. He further posits that MRI 
and cognitive changes can be explained by reference to compensa-
tory mechanisms and cognitive reserve theory after the onset of 
schizophrenia, at the same time as cognitive functioning does not 
get increasingly impaired in the course of the disorder.
Dara Manoach and Robert Stickgold raises the often neglected 
and poorly understood issue of sleep disorders in schizophrenia 
and ask the important question if abnormal sleep impair memory 
consolidation in schizophrenia? Starting with the observation that 
sleep abnormality often impairs cognitive functioning in healthy 
individuals it is imperative to delineate whether a similar relation-
ship exists in mental disorders where cognition is affected. Manoach 
and Stickgold suggests that the evolution of memory consolidation 
over time is facilitated by sleep, and they then review existing data 
that abnormal sleep in schizophrenia disrupts attention and impairs 
sleep-dependent memory consolidation and task automation. The 
authors conclude that these sleep-dependent impairments may con-
tribute substantially to the generalized cognitive deﬁ  cits in schizo-
phrenia and that focus on the amelioration of sleep disturbances 
may have important consequences for clinical improvement.
Åsa Hammar and Guro Årdal review their work on cognitive 
function in patients with major depression, and the question if 
repeated relapses of depressed episodes increasingly impair cogni-
tion and if cognition is similarly restored after symptom treatment 
and restoration of normal functioning. Hammar and Årdal review 
recent research that has focused on cognitive functioning in the 
severe phase of depression, where it is widely accepted that the 
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They then go on to review their own work that has used an experi-
mental approach focusing on attention shift and attentive search 
processes. They show that cognitive impairment remains during 
depressed episodes despite clinical improvement. The authors also 
show that impaired ability to perform the attention tasks employed 
in their studies is related to frequency of depressed episodes and 
with the duration of episodes.
Else-Marie Løberg and Kenneth Hugdahl review available studies 
on a relationship between cannabis use and cognitive functioning 
in schizophrenia. It is an established fact that cannabis use is quite 
frequent in schizophrenia. It has also been suggested that cannabis 
actually can be a contributing causal factor in schizophrenia, which 
may interact with the typical neurocognitive vulnerability seen in 
this patient group. Løberg and Hugdahl reviews the literature and 
of the 23 studies that were found, a clear majority reported either 
improved cognitive functioning or no change, with only one study 
reporting a decline. These paradoxical ﬁ  ndings may be explained by 
several alternative hypotheses. One hypothesis is that the cannabis 
group overall has a better functioning with superior social skills, 
enabling drug acquisition. Another hypothesis is that cannabis use 
could have a positive inﬂ  uence on brain functioning, but taking the 
negative effects of cannabis on brain and psychosis into account, 
this is not probable. A cannabis-related schizophrenia group study 
show poorer prognosis and studies on premorbid functioning are 
inconclusive. The authors speculate that cannabis may, through a 
breakdown of brain function, imitate the typical neurocognitive 
vulnerability seen in schizophrenia.
Jazmin Camchong et al. present two studies from their labora-
tory where they have used diffusion tensor MR imaging (DTI) to 
obtain brain anatomical connectivity information in patients with 
schizophrenia and healthy controls by examining the directional 
organization of white matter microstructure. The authors use DTI 
to address the important question of whether brain connectivity 
and its abnormalities may be heritable traits associated with schizo-
phrenia. The ﬁ  rst study investigated if healthy monozygotic (MZ) 
twin pairs and random pairings among twins would show different 
correlations with regard to DTI measures of neuronal connectivity. 
The results showed that there was a stronger correlation between 
MZ twin pairs than between randomly generated pairs in several 
regions in the brain critically involved in cognitive function. In a 
second study the same approach was applied to ﬁ  rst-degree relatives 
of schizophrenia patients and a healthy control group. The results 
showed that relatives of schizophrenia patients had reduced con-
nectivity in brain regions involved in controlling higher cognitive 
functions. The authors suggest that a DTI connectivity approach 
may be a valuable approach to unravelling new endophenotypes 
in schizophrenia.
Kevin Spencer provides data from a neuro-computational 
approach to elucidate the question of functional consequences of 
cortical circuit abnormalities on gamma oscillations in schizophre-
nia. In particular Spencer uses a computational model of cortical 
circuitry to examine the effects that neural circuit abnormalities 
might have on EEG gamma frequency generation and network 
excitability. The results showed that reducing synaptic connectiv-
ity (e.g. NMDA receptor input) had a negative effect on gamma 
frequency power and phase synchrony. Reducing neuronal spik-
ing activity output impaired gamma generation to a lesser degree 
than reducing synaptic connectivity, thereby increasing network 
excitability. It is suggested that a neuro-computation approach, 
combining non-invasive neurophysiological and structural meas-
ures, might be able to distinguish between different neural circuit 
abnormalities in schizophrenia patients. Computational modelling 
may help to bridge the gaps between post-mortem studies, animal 
models, and experimental data in humans, and facilitate the devel-
opment of new therapies for schizophrenia and neuropsychiatric 
disorders in general.
Godfrey Pearlson and Vince Calhoun ask why endophenotypes 
are important in schizophrenia, and suggest a distinction between 
deﬁ  nitions of endophenotypes versus biomarkers and the impli-
cations of this for the understanding of neurocognitive deﬁ  cits. A 
starting point for their discussion is that because the pathophysi-
ology of schizophrenia is obscure, there is no laboratory test or 
biological marker deriving from the core etiopathology that can 
be reliably used in diagnosis and treatment outcome evaluation. 
Pearlson and Calhoun then review existing data on the relationship 
between abnormal brain functioning and cognitive functioning, 
focusing on activation in the dorsolateral prefrontal cortex and 
adjacent regions and working memory, an often implied endo-
phenotype. The authors identiﬁ  es several problems with current 
approaches to the study of endophenotypes, such as patients not 
understanding the tasks, or task fatigue, and suggest alternative 
approaches such as simpler experimental tasks that might avoid dif-
ﬁ  cult to interprate ﬂ  oor effects. They also advocate the use of resting 
state and default mode network paradigms, applying independent 
component analysis techniques to reveal functional networks rather 
than isolated brain regions when searching for endophenotypes 
and biological markers of schizophrenia.
Emma Thomas and Rebecca Elliott review work related to 
recent research on the neural basis of cognition in depression, 
focusing on the distinction between emotional and non-emo-
tional processing. Cognitive deﬁ  cits are among the core deﬁ  cits 
in depression and also listed in recent diagnostic manuals as core 
symptoms, in particular reduced concentration and poor mem-
ory. Another equally important class of cognitive processes is the 
investigation of mechanisms of emotional disturbance, such as 
negative bias of thoughts and excessive response to failure. The 
article reviews the major emotional and non-emotional cognitive 
processes in depression, together with ﬁ  ndings from neuroimaging 
studies. They conclude on the basis of their review of the data that 
models of cognitive dysfunction in depression is underscored by 
disrupted cortico-limbic circuitry, and discuss how connectivity 
analysis MRI techniques can be used to test such models explicitly, 
revealing important clinical implications of cognitive imaging in 
depression. Understanding of such relationships may have impor-
tant consequences for diagnosis and treatment of depression and 
depressive episodes.
Matcheri Keshavan and colleagues review previous work on pre-
morbid cognitive deﬁ  cits and their relationship to brain structure 
in young relatives of schizophrenia patients. They note cognitive 
deﬁ  cits in the adolescent population which also manifest in ﬁ  rst-
degree relatives. The primary deﬁ  cits include psychomotor speed, 
memory, attention, reasoning, and social-cognition in addition 
to generalized measures such as intelligence. Of note, the age of 
adolescence may be a useful “window” for observing premorbid 
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impairments in neurocognition. They also examine the relationship 
between brain structure and cognitive measures. There is much 
evidence of neurocognitive deﬁ  cits, but more study is needed to 
improve our understanding of their structural underpinnings. In 
addition the potential to use these measures as biomarkers and 
possibly endophenotypes should be explored further.
Daniel Mathalon and colleagues present a study of electrophysi-
ological abnormalities in schizophrenia and schizoaffective disor-
der (SA). In particular, P300 differences including amplitude and 
latency have been widely studied in schizophrenia but have not 
been well studies in SA. Interestingly they found that although P300 
amplitude was preserved in the SA group the latency and reaction 
times were affected similarly in schizophrenia and schizoaffec-
tive disorder. These changes could not be accounted for by other 
measured demographic variables and suggests that the underlying 
pathophysiology of the two groups is different.
Sophia Frangou provides a selective review of cognitive function 
in early onset schizophrenia. Changes in IQ, attention, executive 
function and memory have been observed and in this group, which 
provides a unique way to study the trajectory of the disease in a 
more severe variant of adult onset schizophrenia. Frangou identi-
ﬁ  ed a consistent pattern of abnormalities in the various cognitive 
domains. In addition to ﬁ  nding evidence that the cognitive pro-
ﬁ  le of the early onset group was similar to that of the less severe 
adult onset group she highlighted age related improvements which 
existed for healthy adolescents but not for patients.
Leighton Hinkley and colleagues present a magnetoencepha-
lography (MEG) study of the neural connectivity in  schizophrenia 
patients. They present several approaches for maximizing the 
sensitivity of the MEG technique including adaptive spatial ﬁ  l-
tering, different functional connectivity metrics, and study the 
relationship to various cognitive and clinical outcomes. The 
use of MEG can be used to augment existing work by adaptive 
existing paradigms used in EEG and fMRI to MEG. Finally they 
discuss experimental paradigms which demonstrate important 
utility in relating impaired connectivity to characteristic ﬁ  ndings 
in schizophrenia.
In summary, the current collection of articles represents the 
wide range of topics related to cognitive impairment in schizophre-
nia and depression. In this respect the special topic issue provides 
compelling evidence that cognitive impairment is a primary aspect 
of both schizophrenia and depression, and not secondary to other 
symptoms and disease processes. The current selection of articles 
also show how recent developments in structural and functional 
neuroimaging, including both hemodynamic and electrophysiol-
ogy, may further advance our understanding of how cognition is 
impaired in these disorders. The more complete picture of these 
disorders provided by cognitive measures, neuroimaging, and also 
genetics will likely be important tools in future diagnostics and 
treatment evaluation.
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